PRESS-RELEASE ·Filed Apr 28, 2026

ORKA

Oruka Therapeutics, Inc.
BEARISH
Impact 6/10
Horizondays Processed5mo ago WireGlobeNewswire
Press release: offering
Actionable Insight ▼ Bearish

Expect near-term selling pressure from the dilutive offering. Monitor the stock for potential support around the offering price. The company's cash position strengthens, reducing near-term financing risk.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
ORKA ▲ +35.33% at T+60d
SHORT call ✗ call lost -35.33% · α vs SPY -31.22% · entry $68.10 → $92.16
Entry anchored
Apr 28, 03:59 PM ET
via exchange tick
T+1d
0.00%
call 0.00% · α +1.02%
$68.10
settled 5mo ago
T+5d
+1.25%
call -1.25% · α +1.86%
$68.95
settled 5mo ago
T+20d
-14.85%
call +14.85% · α +20.31%
$57.99
settled 4mo ago
T+60d
+35.33%
call -35.33% · α -31.22%
$92.16
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Oruka Therapeutics priced an upsized underwritten public offering of 9.66 million shares at $72.50 per share, raising approximately $700.4 million in gross proceeds. The substantial dilution (~18% of current shares outstanding) is likely to pressure the stock near term, though the capital bolsters its clinical-stage pipeline.

Key Financial Metrics

Deal Value
$700.4M

Key Facts

  • Offering of 9,660,000 shares at $72.50 per share
  • Gross proceeds of ~$700.4 million
  • Underwriters have 30-day option for additional 1,449,000 shares
  • Expected closing on April 30, 2026
  • Dilution of approximately 18.4% (21.1% including greenshoe)

Financial Impact

~$700.4M gross proceeds; dilution of ~18% of pre-offering shares outstanding

dilution

Risk Factors

  • Further dilution if underwriters exercise the greenshoe option
  • Stock overhang as new shares enter the market
  • Clinical-stage biotech with no approved products; execution risk remains

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3283352
26 reports for ORKA
Performance horizon
100% Hit rate 10 of 10 directional calls best @ T+60▲ +80.05%Jun 1, 2026
Filters
Rows
Reports for ORKA — sortable, filterable
TypeNow
Sep 15, 2026
16d ago
Insider Cluster
NEUTRAL ★ 3/10
$93.55 $89.93▼ −3.87%▼ −6.44%$84.38 (−9.80%)
Sep 1, 2026
4w ago
Insider Cluster
BEARISH ★ 4/10
$91.63 $91.65▼ −0.02%▼ −0.98%$84.38 (+7.91%)
Aug 28, 2026
5w ago
EFFECT
BEARISH ★ 6/10
$91.15 $92.51▼ −1.50%▼ −1.39%$84.38 (+7.42%)
Aug 17, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$113.08 $101.82▼ −9.96%▼ −9.76%$84.38 (−25.38%)
Aug 10, 2026
7w ago
Press Release
BULLISH ★ 7/10
$105.14 $112.66▲ +7.15%▲ +7.20%$84.38 (−19.75%)
Aug 10, 2026
7w ago
8-K
BULLISH ★ 6/10
$105.14 $112.66▲ +7.15%▲ +7.20%$84.38 (−19.75%)
Aug 9, 2026
7w ago
Institutional Cluster
BULLISH ★ 7/10
$105.14 $112.66▲ +7.15%▲ +7.20%$84.38 (−19.75%)
Jul 15, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$83.04 $91.95▲ +10.73%▲ +12.40%$84.38 (+1.61%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 5/10
$85.21 $88.27▲ +3.59%▲ +2.66%$84.38 (−0.97%)
Jun 22, 2026
14w ago
Insider Cluster
NEUTRAL ★ 3/10
$83.40 $92.49▲ +10.90%▲ +9.89%$84.38 (+1.18%)
Showing 10 of 26

US Market Status

Market Open — Closes in 3h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 28, 2026